Hemodynamic,Hemorheologic,and Hemocoagulative Changes After Treatment With Picotamide in Patients Affected by Peripheral Arterial Disease (PAD) of the Lower Limbs
Restricted accessResearch articleFirst published online February, 1994
Hemodynamic,Hemorheologic,and Hemocoagulative Changes After Treatment With Picotamide in Patients Affected by Peripheral Arterial Disease (PAD) of the Lower Limbs
Effects of picotamide on platelet activity and on some hemorheologic, coagu lative, and hemodynamic parameters were investigated in a randomized, dou ble-blind, placebo-controlled study for eighteen months. Twenty patients, average age 61.5±9.6 (SD) years, with peripheral arterial disease (PAD) at functional stage 2 of the Fontaine classification and with intermittent claudica tion for at least six months were studied.
Ten patients received tablets of picotamide, 300 mg three times a day, and 10 subjects received three identical placebo tablets each day. Similar atheroscler otic disease risk factors were present in both groups.
Picotamide induced a significant decrease of plasma viscosity, fibrinogen, and beta-thromboglobulin and an increase of amplitude of the photoplethysmo graphic wave.
Get full access to this article
View all access options for this article.
References
1.
Dintefass L.: Basic aspect of blood rheology. In Hyper-viscosity in Hypertension , ed. by Dintefass L.New York: Pergamon Press, 1981, pp 1-32.
2.
Stoltz JF: Red blood cell microrheology. La Ricerca Clin Lab13 (Suppl 3):53-70, 1983.
3.
Macchione C. , Molaschi M., Neirotti M., et al: Hemodynamic, hemorheological and coagulative changes after treatment with defibrotide in elderly patients affected by chronic arteriopathy of the lower limbs. Arch Gerontol Geriatr12 (Suppl 2):413-416, 1991.
4.
Reunanen A., Takkunen H., Aromaa A.: Prevalence of intermittent claudication and its effect on mortality . Acta Med Scand211:249-256, 1982.
5.
Jelnes R., Gaardsting O., Hougaard Jensen K, et al: Fate in intermittent claudication: Outcome and risk factors . Br Med J293:1137-1139, 1986 .
6.
Criqui MH, Fronek A., Barrett-Connor E., et al: The prevalence of peripheral arterial disease in a defined population . Circulation71:510-515, 1985.
7.
Kannel WB, Skinner JJ, Schwartz MJ, et al: Intermittent claudication: Incidence in Framingham study. Circulation41:875-883, 1970.
8.
Gresele P., Deckmyn H., Arnout J., et al: Characterization of N,N'-bis (3-picolyl)-4-methoxy-isophtalamide (Picotamide) as a dual thromboxane A2 receptor antagonist in human platelets. Thromb Haemostas61:479-484, 1989.
9.
Reid HL, Barnes AJ, Lock PG, et al: A simple method for measuring erythrocyte deformability. J Clin Pathol29:855-858, 1976.
10.
Bo M., Bonino F., Neirotti M., et al: Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology42:106-113, 1991.
11.
Goyle KB, Reid HL, Dormandy JA: Treatment of severe intermittent claudication by controlled defibrination . Lancet1:625-626, 1977.
12.
Wilhelmsen L., Svandsudd MD, Korson-Bengstsen K., et al: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med311:501-505, 1986.
13.
Criqui MH, Langer RD, Fronek A., et al: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med326:381-386, 1992.
14.
Newman AB, Sutton-Tyrrell K., Rutan GH, et al: Lower extremity arterial disease in elderly subjects with systolic hypertension. J Clin Epidemiol44:15-20, 1991.
15.
Hugson WG, Mann JI, Tibbs DJ, et al: Intermittent claudication: Factors determining outcome. Br Med J1:1377-1379, 1978.
16.
Fowkes Fgr: The measurement of atherosclerotic peripheral arterial disease in epidemiologic surveys. Int J Epidemiol17:248-254, 1988.
17.
Smith GD, Shipley MJ, Rose G.: Intermittent claudication, heart disease risk factors and mortality: The Whitehall Study. Circulation82:1925-1931, 1990 .
18.
Aronow WS, Sales FF, Etienne F., et al: Prevalence of peripheral arterial disease and its correlation with risk factors for peripheral arterial disease in elderly patients in a long-term care facility. Am J Cardiol62:644-645, 1988.
19.
Gordon T., Kannel WB: Predisposition to atherosclerosis in the head, heart, and legs. The Framingham Study. JAMA221:661-666, 1972.
20.
Meade TW, Mellows S., Brozovic M., et al: Haemostatic function and ischaemic heart disease: principal results of the Northwich Park Heart Study. Lancet6:533-537, 1986.
21.
Svanborg A. : 70-year-old people in Gothenburg. A population in an industrialized Swedish city. II. A general presentation of social and medical conditions. Acta Med Scand611 (Suppl):5-37, 1977.
22.
Kannel WB, Wolf PA, Castelli WP, et al: Fibrinogen and risk of cardiovascular disease. JAMA258:1183-1186, 1987.
23.
Coto V., Cocozza M., Oliviero U., et al: Clinical efficacy of Picotamide in long-term treatment of intermittent claudication. Angiology40:880-885, 1989.
24.
Antiplatelets Trialists' collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J296:320-331, 1988.
